Amr Yafi, MD
Nephrology · Chicago, ILNPI 1558597047
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,400 of the $71,445 with a category attached, or 73.3%. Amgen accounts for 86.8% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $17,678 and has fallen 53.6% since, to $8,207 in 2025. Among nephrology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $327.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$62K
- Sobi, Inc$6K
- Baxter Healthcare$1K
- AstraZeneca$774
- Mallinckrodt Hospital Products Inc.$274
- Fresenius USA Marketing, Inc.$112
- plus $933 from 17 others
What the payments were for
- Consulting fees$5,4568%
- Speaking & faculty fees$52,40073%
- Travel & lodging$7,56511%
- Food & beverage$5,9318%
- Education$930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 122 | $62,035 |
| Sobi, Inc | 6 | $5,952 |
| Baxter Healthcare | 10 | $1,365 |
| AstraZeneca | 31 | $774 |
| Mallinckrodt Hospital Products Inc. | 5 | $274 |
| Fresenius USA Marketing, Inc. | 2 | $112 |
| Vifor Pharma, Inc. | 7 | $105 |
| Boehringer Ingelheim | 4 | $94 |
| Aurinia Pharma U.S., Inc. | 1 | $87 |
| Otsuka America Pharmaceutical, Inc. | 5 | $87 |
| Vantive US Healthcare LLC | 2 | $86 |
| Novartis | 4 | $84 |
| Ardelyx, Inc. | 2 | $82 |
| Bayer | 4 | $77 |
| Avita Medical Americas, LLC | 2 | $42 |
| Mallinckrodt Enterprises LLC | 3 | $42 |
| Travere Therapeutics, Inc. | 1 | $28 |
| Veloxis Pharmaceuticals, Inc. | 1 | $23 |
| OPKO Pharmaceuticals, LLC | 1 | $22 |
| Calliditas Therapeutics US Inc. | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Merck | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$60,249
- Non-Franchise (NOF) - NonProduct$960
- Synagis$382
- Renal - Acute$150
- ACTHAR$142
- LOKELMA$127
- FARXIGA$105
How this compares
$71,445 in reported general payments places this provider in the 95th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 56 | $52,328 |
| VelphoroSucroferric Oxyhydroxide | 14 | $32,434 |
| Sevelamer Carbonate | 29 | $6,983 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $5,771 |
| Allopurinol | 32 | $310 |
| Nifedipine ErNifedipine | 19 | $296 |
| Carvedilol | 19 | $141 |
| Lisinopril | 18 | $119 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 13 | $86 |
| Amlodipine Besylate | 19 | $84 |
| Furosemide | 19 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $774 | $58,09968 claims |
| Fresenius USA Marketing, Inc.Velphoro | $112 | $32,43414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 524 nephrology providers in Illinois.
Other nephrology in Chicago
- Myles WolfChicago$2.1M
- Susan QuagginChicago$262K
- Nicole StankusChicago$235K
- Marco BonillaChicago$148K
- Lorenzo GallonChicago$120K
- Vikram AggarwalChicago$117K
- Jay KoynerChicago$113K
- Jose ArrudaChicago$107K
- John FriedewaldChicago$93K
- Casey GashtiChicago$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.